Research programme: small molecule therapeutics - Suzhou NeuPharma

Drug Profile

Research programme: small molecule therapeutics - Suzhou NeuPharma

Alternative Names: RX 101; RX 208

Latest Information Update: 10 Jun 2015

Price : $50

At a glance

  • Originator Suzhou NeuPharma
  • Class Antineoplastics; Neuropsychotherapeutics; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer; Neurodegenerative disorders

Most Recent Events

  • 10 Jun 2015 Early research in Cancer and Neurodegenerative disorders in China (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top